Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 5.6% Potential Decrease Indicated by Barclays Capital

Hikma Pharmaceuticals Plc 5.6% Potential Decrease Indicated by Barclays Capital

Hikma Pharmaceuticals Plc with EPIC/TICKER (LON:HIK) has had its stock rating noted as ‘Downgrades’ with the recommendation being set at ‘UNDERWEIGHT’ this morning by analysts at Barclays Capital. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set a target price of 800 GBX on its stock. This would indicate that the analyst believes there is a downside of -5.6% from the opening price of 847.6 GBX. Over the last 30 and 90 trading days the company share price has decreased 154.4 points and decreased 200.4 points respectively. The 52 week high share price is 2346 GBX while the year low share price is currently 814.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,011.99 GBX and a 200 day moving average of 1,224.47. There are currently 111,474,835 shares in issue with the average daily volume traded being 532,980. Market capitalisation for LON:HIK is £2,043,296,102 GBP.

Follow this article (for updates)
X

Follow this article (for updates)

E-mail : *
* Your personal data will be used to support your experience throughout this website and for other purposes described in our Privacy Policy. I hereby agree and consent to the privacy policy.